🇺🇸 FDA
Pipeline program

QR-504a

PQ-504a-001

Phase 1 small_molecule terminated

Quick answer

QR-504a for Fuchs Endothelial Corneal Dystrophy is a Phase 1 program (small_molecule) at ProQR Therapeutics N.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
ProQR Therapeutics N.V.
Indication
Fuchs Endothelial Corneal Dystrophy
Phase
Phase 1
Modality
small_molecule
Status
terminated

Clinical trials